Status:
COMPLETED
Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.
Eligibility Criteria
Inclusion
- Advanced solid tumors suitable for treatment with Taxanes, with or without carboplatin, or treatment with Capecitabine, Gemcitabine/Cisplatin. or Pemetrexed/Cisplatin
Exclusion
- Tumors abutting or providing support for blood vessels
- Any significant gastrointestinal abnormalities or active bleeding.
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00454649
Start Date
December 1 2005
End Date
April 1 2011
Last Update
April 4 2012
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Augusta, Georgia, United States, 30909
2
Pfizer Investigational Site
Augusta, Georgia, United States, 30912
3
Pfizer Investigational Site
Harvey, Illinois, United States, 60426-4265
4
Pfizer Investigational Site
Harvey, Illinois, United States, 60426